Advancing Cancer Care Through Predictive Pathology
Our aim is to help physicians and patients make personalized decisions about cancer care, and to enhance the bio-pharmaceutical development of more effective cancer treatments.
Aureon Laboratories utilizes a unique "Systems Pathology" approach to develop predictive tests for individual cancer recurrence and provides clinical research services to assist in bio-pharmaceutical development of oncology therapeutics.
Headlines:
Aureon Laboratories Names Ana I. Stancic Chief Financial Officer - Twenty-year healthcare industry veteran aboard as company prepares to launch new prostate cancer prognostic test » more
Aureon Presents Poster at ASCO GU Symposium: "Androgen Receptor levels in both needle biopsy and prostatectomy specimens are associated with overall survival in castration resistant disease" » more
Aureon Laboratories to Collaborate with Pfizer, Inc. to Establish Quantitative Biometrics for Assessing Therapeutic Response of Prostate Cancer Patients Treated with Hormone Therapy » more
Aureon Laboratories to present at 19th Annual Piper Jaffray Health Care Conference
Wednesday, November 28, 2007 1:50pm at The Pierre New York, NY » schedule
Aureon to Collaborate with UCSF to Construct Predictive Models for GM-CSF Treatment Response in Patients with Prostate Cancer » more
Aureon Laboratories Completes Initial Study with AstraZeneca Using Predictive Pathology to Stratify Patient Risk for Non-Small Cell Lung Cancer » more
Aureon Paper: "Improved Prediction of Prostate Cancer Recurrence Through Systems Pathology" Published in JCI » more
Aureon Laboratories and Prostate Px are registered trademarks of Aureon Laboratories, Inc.
